Navicixizumab (Anti-DLL4)
Product Specifications
CAS Number
1638338-43-8
Synonyms
OMP-305B83; Anti-DLL4 Reference Antibody
Additionnal Information
Navicixizumab (Anti-DLL4) is a bispecific monoclonal antibody targeting DLL4/VEGF. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. MW: 145.5 KD.
Storage Conditions
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
27562121 3x 1.0µg DNA
LPGAT1P1 CRISPRa sgRNA lentivector (set of three targets)(Human)
Sign In for Pricing
View Details